# US 2016/0256382 A1 · Sustained-release reservoir implants for intracameral drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256382 A1
- Document ID: US20160256382A1
- Status: Published application
- Kind: A1
- Application number: 15/159,418
- Filed: 2016-05-19
- Published: 2016-09-08
- Earliest claimed: 2010-04-06
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Ruiwen Shi; Patrick M. Hughes; James A. Burke; Michael R. Robinson; Hui Liu
- Web page: https://patentgrep.com/patent/US20160256382A1

## CPC

- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61K 31/382: having six-membered rings, e.g. thioxanthenes (thiothixene A61K31/496)
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 31/5578: having a pentalene ring system, e.g. carbacyclin, iloprost
- A61P 9/12: Antihypertensives
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (IOP), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days.

## Claims

### Claim 1

A sustained release implant for intraocular use to treat elevated intraocular pressure, configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (lOP), said implant comprising a core, which is fabricated as a bundle of individual fibres comprising an antihypertensive agent, said core is surrounded by a non-biodegradable polymer which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient, wherein:
the antihypertensive agent is selected from the group consisting of bimatoprost, latanoprost, travoprost, unoprostone, EP2/EP4 receptor agonists, timolol, betaxolol, levobetaxolol, carteolol, levobunolol, propranolol, brirnonidine, apraclonidine, epinephrine, dipivefrin, pilocarpine, Latrunculin B compound, vaptans, anecortave acetate, ethacrynic acid, cannabinoids, brinzolamide, acetazolamide and EP2 receptor agonists; and
the implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive into said eye for a period of time of between 12 days and 365 days.

### Claim 2 (depends on 1)

The implant of claim 1, wherein the non-biodegradable polymer is selected from the group consisting of silicone elastomers, poly(ethylene-co-vinylacetate) and polyurethane.

### Claim 3 (depends on 1)

The implant of claim 1, wherein the antihypertensive agent is selected from the group consisting of bimatoprost, latanoprost, travoprost, unoprostone, EP2 receptor agonists, and EP2/EP4 receptor agonists.

### Claim 4 (depends on 1)

The implant of claim 1 wherein antihypertensive agent is a combination of ocular anti-hypertensives.

### Claim 5 (depends on 4)

The implant of claim 4 wherein said combination is selected from the group consisting of bimatoprost/timolol, travoprost/timolol, latanoprost/timolol and brimonidine/timolol.

### Claim 6 (depends on 1)

The implant of claim 1, wherein said antihypertensive agent is an EP2 agonist.

### Claim 7 (depends on 1)

An antihypertensive agent for use in treating elevated intraocular pressure, wherein the treatment comprises intracameral or anterior vitreal administration, to a patient with elevated intraocular pressure (IOP), of a sustained release implant according to claim 1.

### Claim 8 (depends on 7)

The antihypertensive agent for use according to claim 7, wherein said implant comprises from about 10 to about 50 weight percent of said anti-hypertensive agent and from 50 to 90 weight percent of said polymer.
